No Data
The Advanced Reading Strategy Command Room = Quoripsis: Gained STAR in regenerative medicine, and is also attracting attention at the Osaka Expo.
Qualips <4894.T> is a biotech venture stock gaining popularity due to its theme of regenerative medicine. It tends to have significant price fluctuations, making it a target for spot buying with the aim of capitalizing on dips. This biotech venture was established by Osaka Universities. On the 8th, it was announced that they had submitted an application for manufacturing and sales approval of human iPS cell-derived myocardial cell sheets for the treatment of severe heart failure due to ischemic cardiomyopathy to the Ministry of Health, Labour and Welfare, resulting in the stock price hitting its daily limit up on the 9th. However, the all-time high since listing is 10,500 yen (on September 27, 2024).
Our CTO, Saw, was interviewed by NHK WORLD-JAPAN NEWS.
Our CTO, Sawa, was interviewed by NHK WORLD-JAPAN NEWS on 2025/04/18. For more details, please watch the video at the link (NHK WORLD-JAPAN Official YouTube channel). Future innovations on display at Osaka Expo - NHK WORLD-JAPAN.
Cuorips: (Exchange) Changes in “Financial Results Explanatory Materials for the 3rd Quarter of the Fiscal Year Ending March 31, 2025”
Cuorips: (Exchange) Changes in “Financial Results Explanatory Materials for the 2nd Quarter of the Fiscal Year Ending March 31, 2025”
Growth 250 plummeted, with declines in SanBio ETC = Emerging Markets, September 9.
The Tokyo Stock Exchange Growth Market 250 Index has sharply declined. Due to concerns over a trade war, there is a tendency for stock prices to drop again, with Emerging Markets also experiencing widespread losses. Major stocks such as Cover <5253.T> and SanBio <4592.T> have fallen. The drops of Genda <9166.T> and iSpace <9348.T> were also noticeable. Qualips <4894.T> and Heartseed <219A.T> have increased. In the Standard sector, Harmonic Drive Systems <6324.T> has reached new lows.
CellSeed - temporarily reached the upper limit, with a rapid rise in Qualisys expanding interest in drug discovery-related stocks.
The stock reached a temporary high. Qualips <4894> announced its application for manufacturing and selling regenerative medicine products derived from iPS cell-derived cardiac muscle cell sheets, which has led to a surge in buying interest, reaching a stop-high buying indication, expanding into drug discovery-related stocks. Besides Cellseed, K Pharma <4896> and Heartseed <219A> are also rapidly rising. Cellseed disclosed the start of clinical trials for allogenic cartilage cell sheets on March 24, which seems to be attracting renewed buying interest.
